Wegovy pill is the next chapter in our decades-long GLP-1 experience. Clinical evidence & efficacy Approval was based on results from the OASIS 4 phase 3 clinical trial, a 71-week, double-blind, randomised, placebo-controlled trial that included 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes
Cinnamon has been studied for its effects on blood sugar regulation and insulin sensitivity
Retatrutide , the newest entry, activates three receptors: GLP-1, GIP, and glucagon
Gastrointestinal symptoms such as mild digestive discomfort affect some patients, though severe reactions are uncommon
Peer-reviewed Phase 2 and TRIUMPH program-design papers exist, but they do not replace the Phase 3 results report
Clinical averages don't tell the full story